RCE recce pharmaceuticals ltd

Recce Pharmaceuticals (RCE) expects more data to be released in...

  1. 7,926 Posts.
    lightbulb Created with Sketch. 1230
    • Recce Pharmaceuticals (RCE) expects more data to be released in the coming months from several clinical studies of its anti-infectives
    • The company says first patient dosing will get underway in August for its Intravenous (I.V.) Phase I Human Clinical Trial, which is set to run for one year
    • By Q4 2021, RCE expects data to begin arriving from its Topical Phase I/II Human Burns Study, with the eight-month trial recently getting underway in WA
    • Around the same time, Recce says it should also begin receiving data from its SARS-CoV-2 (COVID-19) International Studies despite a recent delay

    Read the Full Article on The Market Herald here
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
38.5¢
Change
0.000(0.00%)
Mkt cap ! $111.3M
Open High Low Value Volume
38.5¢ 38.5¢ 38.5¢ $100 259

Buyers (Bids)

No. Vol. Price($)
2 20015 38.0¢
 

Sellers (Offers)

Price($) Vol. No.
39.0¢ 50145 2
View Market Depth
Last trade - 10.00am 31/07/2025 (20 minute delay) ?
RCE (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.